BPC-157 + TB-500: The Wolverine Stack Research Protocol

BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, a molecular weight of 1419.6 g/mol and CAS number 137525-51-0. It derives from a fragment of a protein found in human gastric juice and was characterised at the University of Zagreb in the early 1990s. Its most distinctive property is not a receptor interaction at all: the intact peptide survives incubation in native gastric juice at pH 1 to 2 with pepsin. The sequence carries no methionine, cysteine, tryptophan, asparagine or glutamine, which leaves hydrolysis at the Asp10 to Asp11 bond as its primary chemical liability.

TB-500 is far smaller than most people assume. The compound sold under that name is the N-acetylated heptapeptide Ac-LKKTETQ, molecular weight 889.0 g/mol, CAS number 885340-08-9. It corresponds to the actin-binding active site of thymosin beta-4, a 43 residue, roughly 4.9 kDa protein and one of the most abundant intracellular peptides in mammalian tissue. Anti-doping laboratories list it as N-acetyl-LKKTETQ, because the brand name says nothing about structure.

A 7 amino acid fragment and a 43 amino acid protein are not interchangeable, yet vendors use "TB-500" and "Thymosin Beta-4" as if they were. Five milligrams of each are different molar quantities, reconstitute to different concentrations and carry different specifications, and the substitution is not visible on the label.

The case for stacking is mechanistic, and it is not stupid.

• BPC-157 activates VEGFR2 signalling and, through the Akt and eNOS axis, increases nitric oxide availability and angiogenesis, engages ERK1/2, promotes fibroblast activity and collagen deposition, and modulates inflammatory signalling, with the proposed value in poorly vascularised tissue such as tendon.
• Thymosin beta-4 sequesters G-actin monomers and regulates their polymerisation into F-actin, the machinery cells use to migrate, and forms a complex with PINCH and integrin-linked kinase that activates Akt. In a rat full-thickness wound model, topical or intraperitoneal thymosin beta-4 increased reepithelialisation by 42 percent at day 4 and up to 61 percent at day 7, increased contraction by at least 11 percent, and stimulated keratinocyte migration two to threefold at picogram amounts in vitro.

Framed that way the pairing looks complementary: vasculature and matrix from one side, cell migration and cytoskeletal remodelling from the other. The weak point is convergence. Both compounds act on the same downstream node, Akt with eNOS involvement, and BPC-157's literature already lists fibroblast and endothelial migration. Two agents pulling the same handle do not double the pull, and the only in vivo combination study found redundancy rather than addition.

Bottom line: the rationale is plausible pharmacology, not demonstrated synergy. Plausibility justifies a controlled study. It does not justify assuming the result.

In 2026, a group in Turkey published in Joint Diseases and Related Surgery what is currently the only controlled test of the pair as a pair. Thirty-two male Sprague-Dawley rats, twelve weeks old and roughly 330 grams, underwent standardised Achilles tendon transection and repair and were randomised into four groups of eight: control, BPC-157 at 10 micrograms per kilogram per day, TB-500 at 60 micrograms per kilogram per day, and both combined. All treatments were given intraperitoneally for four weeks.

Endpoints were well chosen: maximum load to failure, Bonar and Movin histology across four stains, and collagen I and III H-scores.

Three results matter for anyone reading stack claims:

• Both treatment groups showed higher maximum load to failure than controls, with statistical significance in the TB-500 group (p < 0.05).
• Histopathology improved in both groups, with better extracellular matrix organisation during early tendon repair.
• The combination arm did not outperform the single-agent arms. The authors state that the absence of additive effects may reflect convergence on shared downstream pathways, and that the hypothesis needs further experimental confirmation.

Two limits temper the reading. The arms were not dose-matched, since 60 micrograms per kilogram of TB-500 is six times the BPC-157 dose in the same experiment. And this is exploratory work with eight animals per group, one species, one tendon model, a four week window and an intraperitoneal route no human protocol uses. It does not establish synergy. It calls one specific synergy claim into question.

BPC-157 has three pilot studies. A 2025 scoping review in Current Reviews in Musculoskeletal Medicine counted the entire human dataset: intraarticular knee pain, interstitial cystitis, and an intravenous safety and pharmacokinetic study. Fewer than 30 subjects, no control groups, no standardised preparations, no reported adverse effects. A 2026 review in Pharmaceutics adds a pharmacokinetic picture that is uncomfortable for the way the compound is discussed. The confirmed plasma half-life is under 30 minutes in both preclinical species and in the only human pilot, with intramuscular bioavailability of 14 to 19 percent in rats against 45 to 51 percent in dogs. Prolonged biological effects in animal models therefore cannot be explained by plasma exposure, and the half-life of around four hours quoted in vendor material is not supported by the data.

TB-500 itself has almost no data. A 2024 analytical paper in the Journal of Chromatography B that developed a method to quantify the compound and its metabolites states the position directly: the biological effects of TB-500 itself have not been documented. What exists is parent protein data applied to a fragment by assumption.

That parent protein literature is real and worth separating from the fragment claims. Cardiovascular Research published a randomised, placebo-controlled, double-blind trial of recombinant human thymosin beta-4 in 96 patients with ST-elevation myocardial infarction after PCI. Infarcted areas were significantly reduced in the subgroup dosed within eight hours of PCI (n = 43) at 90 days, while the difference across the full cohort was not statistically significant. A real randomised trial, but with a recombinant protein, an intravenous route and a cardiac indication. It says nothing about a 7 residue fragment in a tendon.

Regulatory status is not a safety verdict in either direction. BPC-157 previously sat in FDA Category 2 for bulk drug substances under Section 503A, the category for substances with safety concerns or insufficient clinical utility for compounding. The FDA removed it on 15 April 2026 after the original nominators withdrew, an administrative event and not a finding on safety or efficacy, and the Pharmacy Compounding Advisory Committee was scheduled to review BPC-157 for the 503A bulks list on 23 July 2026. The World Anti-Doping Agency listed BPC-157 in 2022 under S0 for unapproved substances and later reversed that listing, reflecting detection difficulty rather than any conclusion about risk, while TB-500 remains a routine target analyte in doping-control methods. Neither compound is approved anywhere, neither has completed a phase 2 programme, and a 2026 review in Sports Medicine concludes that unapproved peptides show favourable tissue repair in animals while rigorous human safety data stay scarce.

If both compounds are in a protocol, the handling arithmetic doubles. The working concentrations are not the same for the two vials.